Published in:
01-01-2013 | Original Article—Liver, Pancreas, and Biliary Tract
Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors
Authors:
Ming-Huang Chen, Yi-Chen Yeh, Yi-Ming Shyr, Yi-Hua Jan, Yee Chao, Chung-Pin Li, Shin-E Wang, Cheng-Hwai Tzeng, Peter Mu-Hsin Chang, Chun-Yu Liu, Ming-Han Chen, Michael Hsiao, Chi-Ying F. Huang
Published in:
Journal of Gastroenterology
|
Issue 1/2013
Login to get access
Abstract
Background
Gremlin 1 (GREM1) is a bone morphogenetic protein antagonist and a novel proangiogenic factor. Our aim was to evaluate the prognostic value of GREM1 expression and GREM1-related factors in tumor-associated angiogenesis in pancreatic neuroendocrine tumors (NETs).
Methods
The immunohistochemical expression of GREM1 and microvessel density (MVD) were examined in 35 patients with pancreatic NETs and then compared with other clinicopathologic characteristics, including the World Health Organization classification.
Results
The presence of expression of GREM1 (p = 0.016) and high MVD (p = 0.020) were significant and favorable prognostic factors. Moreover, GREM1 expression was significantly associated with high MVD (p = 0.011). MVD was significantly higher in well-differentiated NETs than in well-differentiated or poorly differentiated neuroendocrine carcinomas (p < 0.001).
Conclusions
GREM1 expression was correlated with tumor-associated angiogenesis and was found to be a novel prognostic marker in pancreatic NETS. Our data support a tumor suppressor role of GREM1 in pancreatic NETs.